adalimumab + infliximab + ustekinumab + golimumab + vedolizumab

This entry refers to a group of five distinct biological therapies—adalimumab, infliximab, ustekinumab, golimumab, and vedolizumab—that are being evaluated for their comparative efficacy in the treatment of Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis. These agents represent different classes of biologics: TNF-alpha inhibitors (adalimumab, infliximab, golimumab), an IL-12/IL-23 inhibitor (ustekinumab), and an integrin receptor antagonist (vedolizumab). The specific context for this grouping is a clinical study (NCT05861427) conducted by Assiut University in Upper Egypt to assess the one-year outcomes of patients receiving these various treatments in a real-world setting. Each drug is a monoclonal antibody that targets specific pro-inflammatory pathways to induce and maintain remission in patients with moderate-to-severe IBD.